Skip to content
thestock.space

Thyrocare Technologies (THYROCARE) had a P/E of 55.0× on 6 Nov 2026, above the industry P/E of 52.8×, and the shares are 26% below their 52-week high. Sales and net profit grew 17% and 36% a year over 3 years; its ROCE of 34% is the highest among the 7 largest Diagnostics & Research peers. Debt is 0.10× equity, and its dividend yield is 1.9%. It is a small-cap company with a market cap of ₹7,848 Cr, ranked 6th of 18 Diagnostics & Research companies by market cap; the shares rose 8.3% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹489.75
Day high
₹496.45
Day low
₹484.45
Prev. close
₹489.75
Volume
2.2 L

Health check

1 good · 4 fair · 1 to check
  • ReturnsIn line

    +8.3% over a year, better than 3 of 7 peers.

  • Price tagIn line

    P/E 55.0 vs industry 52.8.

  • GrowthSteady

    Sales +16.7%, profit +36.2% a year over 3 years.

  • ProfitabilityStrong

    ROCE 33.8% vs peer median 18.1%.

  • Balance sheetFair

    Debt 0.10× equity, interest covered 77.0×, Piotroski 5 of 9.

  • Red flags2 to check

    Quarterly profit down 68.4% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Diagnostics & Research

17 listed peers. Screen the industry

Small cap

₹7,848 Cr, #6 of 18 in its industry by size.

Defensive

Beta 0.50 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹930 Cr · profit ₹144 Cr
Market cap
₹7,848 Cr
Small cap
P/E
55.0
Industry 52.8
Price to book
14.75
Peers 7.17
Dividend yield
1.89%
ROE
26.4%
Peers 15.1%
ROCE
33.8%
Peers 18.1%
Debt to equity
0.10
Debt ₹57 Cr
EPS (TTM)
₹8.97
Face value ₹10
OPM (TTM)
27.8%
Net margin 15.5%
Sales growth
+25.1%
Latest quarter vs a year ago
Profit growth
−68.4%
Latest quarter vs a year ago
Price to sales
8.44
EV/EBITDA 28.6

Strengths and risks

Strengths

  • Return on equity of 26.4%.
  • Return on capital employed of 33.8%.
  • Quarterly sales up 25.1% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Quarterly profit down 68.4% on a year ago.
  • Promoter stake down from 60.9% to 51.0%.

Derived automatically from reported figures. Not a recommendation.

About Thyrocare Technologies

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in…

Headquarters
Navi Mumbai
Employees
1,906
Sector
Healthcare
ISIN
INE594H01019
Website
thyrocare.com

Price range

52 weeks

₹342.55₹662.00

Today

₹484.45₹496.45
Avg volume (3M)
5.6 L
1-year return
plus 8.3%
From 52-week high
minus 25.5%

Analyst consensus

5 analysts
Strong buyMean target ₹681.00 plus 38.1%

Target range, with today’s price

Low ₹615.00High ₹730.00

Today’s price ₹493.10 is below the lowest analyst target.

Consensus from Yahoo Finance. Not a recommendation.

Peers · Diagnostics & Research

Compare with peersScreen the whole industry
Company
SAILIFESai Life Sciences1,785.10plus 11.95%37,929101.515.2218.1%15.1%28.7%21.3%226.8%0.00%plus 72.7%
LALPATHLABDr. Lal Path Labs1,970.00plus 0.16%32,94156.511.9925.7%22.6%30.2%11.1%28.3%1.02%plus 24.7%
SYNGENESyngene International417.30plus 0.77%16,77290.33.468.3%3.9%25.7%5.4%−12.0%0.30%minus 36.0%
VIJAYAVijaya Diagnostic Centre1,468.60plus 2.15%15,12674.414.2919.1%21.2%43.1%21.0%26.9%0.14%plus 40.2%
METROPOLISMetropolis Healthcare568.75minus 0.39%11,80352.87.1715.7%14.6%21.7%12.7%10.0%0.35%plus 12.5%
THYROCAREThyrocare Technologies493.10plus 0.68%7,84855.014.7533.8%26.4%32.2%16.7%36.2%1.89%plus 8.3%
VIMTALABSVimta Labs496.45minus 2.14%2,21927.94.5221.0%17.7%34.7%8.9%17.2%0.40%minus 23.3%
SURAKSHASuraksha Diagnostic333.55plus 0.68%1,73748.57.0714.7%14.1%21.8%17.7%70.3%0.15%plus 2.2%
Median of 7 peers–0.68%15,12656.57.1718.1%15.1%28.7%12.7%26.9%0.30%12.5%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26Sep 26
193–196224240271
135–138149163222
57.8–57.875.177.348.7
29.9%–29.6%33.5%32.2%18.0%
4.9–5.44.94.945
0.8––1.51.41.6
11.4–21.61412.513.5
––−6.2––−45
50.5–35.464.468.333.7
24.1%–20.7%24.4%24.8%54.8%
38.9–2947.152.215.9
–3.001.812.983.220.96

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+16.7%
Profit CAGR 3Y
+36.2%
EPS CAGR 3Y
+36.1%
ROE
26.4%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
517568681822
–+9.8%+19.9%+20.7%
394428490559
123140191263
23.8%24.6%28.1%32.0%
0.52.63.95.4
2.44.23.12.8
38.74755.358.6
5.84.98.85.6
88.696145213
27.4%27.6%37.6%23.5%
64.570.891.5163
–+9.7%+29.3%+78.2%
4.054.455.7410.21

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
52.95353159
481474494426
23.342.324.750.7
75.174.8121111
633644693747
194204198209
1.62.614.23.1
6.3–1.1–
151177192231
280261287304
633644693747

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
129168180213
−39−91.3−41.1−23
−86.2−84.8−130−170
4.1−8.58.420.6
−43.7−61.6−33.5−20.9
85.7106146192
−79.4−95.3−95.3−148

Shareholding pattern

Source: NSE filings
51.0%
promoters
  • Promoters51.02%
  • Public48.98%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202651.02%48.98%minus 9.90
30 Jun 202660.92%39.08%0.00
31 Mar 202660.92%39.08%minus 0.01
31 Dec 202560.93%39.07%0.00
1 Dec 202560.93%39.07%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you